Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study
Background - Nivolumab-based therapies are efficacious with acceptable safety in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Novel nivolumab-based combination immunotherapies may offer enhanced efficacy in these indications. FRACTION-GC was a signal-seeking, random...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 January 2025
|
| In: |
ESMO open
Year: 2025, Jahrgang: 10, Heft: 2, Pages: 1-10 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2024.104107 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2024.104107 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702924018787 
|
| Verfasserangaben: | G. Ku, G.M. Haag, H. Park, V.K. Lam, T.J. George, S.S. Kim, M. Gutierrez, V. Shankaran, S. Stein, C.S. Denlinger, E. Elimova, A. Nagrial, A.R. He, M.B. Sawyer, H.H. Yoon, R. Geva, J. Starr, G. Curigliano, T. Golan, R. von Moos, R. Fritsch, D. Lim, Q. Wang, A. Patel, T. Aoyama, M. Lei, D. Greenawalt, and M. Di Bartolomeo |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1930547773 | ||
| 003 | DE-627 | ||
| 005 | 20250913141731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250715s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2024.104107 |2 doi | |
| 035 | |a (DE-627)1930547773 | ||
| 035 | |a (DE-599)KXP1930547773 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ku, Geoffrey |e VerfasserIn |0 (DE-588)137157829X |0 (DE-627)1930548206 |4 aut | |
| 245 | 1 | 0 | |a Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer |b the phase II FRACTION gastric cancer study |c G. Ku, G.M. Haag, H. Park, V.K. Lam, T.J. George, S.S. Kim, M. Gutierrez, V. Shankaran, S. Stein, C.S. Denlinger, E. Elimova, A. Nagrial, A.R. He, M.B. Sawyer, H.H. Yoon, R. Geva, J. Starr, G. Curigliano, T. Golan, R. von Moos, R. Fritsch, D. Lim, Q. Wang, A. Patel, T. Aoyama, M. Lei, D. Greenawalt, and M. Di Bartolomeo |
| 264 | 1 | |c 10 January 2025 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.07.2025 | ||
| 520 | |a Background - Nivolumab-based therapies are efficacious with acceptable safety in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Novel nivolumab-based combination immunotherapies may offer enhanced efficacy in these indications. FRACTION-GC was a signal-seeking, randomized, open-label, phase II adaptive-design trial assessing efficacy and safety of nivolumab in combination with ipilimumab [cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody], relatlimab (lymphocyte-activation gene 3 antibody), or IDO1i (BMS986205, an indoleamine-2,3-dioxygenase-1 inhibitor) in patients with unresectable, advanced/metastatic GC/GEJC. - Patients and methods - Previously treated patients with GC/GEJC were randomized to receive nivolumab + ipilimumab, nivolumab + relatlimab, or nivolumab + IDO1i across two tracks: anti-programmed death-(ligand) 1/anti-CTLA-4-naïve (track 1) and -experienced (track 2). Primary endpoints were objective response rate (ORR) by investigator per RECIST v1.1, duration of response, and progression-free survival (PFS) rate at 24 weeks. Secondary endpoint was safety. - Results - Eighty-one patients in track 1 and 81 in track 2 received one combination therapy. With a median follow-up of 50.2 months, ORR [95% confidence interval (CI)] by investigator for nivolumab + ipilimumab, nivolumab + relatlimab, and nivolumab + IDO1i in track 1 was 4% (0.1% to 21.9%), 5% (0.1% to 24.9%), and 13% (4.4% to 28.1%), and for track 2 was 9% (1.1% to 28.0%), 6% (0.7% to 18.7%), and 0% (0% to 15.4%), respectively. PFS rate at 24 weeks (95% CI) was 24% (11% to 39%) for nivolumab + IDO1i track 1, 17% (16% to 32%) for nivolumab + relatlimab track 2, and not estimable for other treatment arms. Grade 3/4 treatment-related adverse events were reported in 22%, 5%, and 18% of patients receiving nivolumab + ipilimumab, nivolumab + relatlimab, and nivolumab + IDO1i in track 1 and in 35%, 11%, and 18% of patients in track 2, respectively. No treatment-related deaths were reported. - Conclusions - While ORR did not meet prespecified expansion criteria in any treatment arm, the safety profile of the combinations was manageable. FRACTION-GC represents a novel adaptive protocol for testing multiple combination immunotherapies. | ||
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a gastroesophageal junction cancer | |
| 650 | 4 | |a immunomodulatory combination therapy | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a relatlimab | |
| 700 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 700 | 1 | |a Park, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lam, V. K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a George, T. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, S. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutierrez, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shankaran, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stein, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denlinger, C. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Elimova, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nagrial, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a He, A. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sawyer, M. B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yoon, H. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geva, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Starr, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Curigliano, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Golan, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Moos, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fritsch, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lim, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Q. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Patel, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aoyama, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lei, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Greenawalt, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Di Bartolomeo, M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 10(2025), 2 vom: Feb., Artikel-ID 104107, Seite 1-10 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer the phase II FRACTION gastric cancer study |
| 773 | 1 | 8 | |g volume:10 |g year:2025 |g number:2 |g month:02 |g elocationid:104107 |g pages:1-10 |g extent:10 |a Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer the phase II FRACTION gastric cancer study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2024.104107 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702924018787 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250715 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 133390934 |a Haag, Georg Martin |m 133390934:Haag, Georg Martin |d 910000 |d 910100 |d 50000 |e 910000PH133390934 |e 910100PH133390934 |e 50000PH133390934 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1930547773 |e 4746481377 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"10 S."}],"relHost":[{"title":[{"subtitle":"cancer horizons","title":"ESMO open","title_sort":"ESMO open"}],"disp":"Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer the phase II FRACTION gastric cancer studyESMO open","note":["Gesehen am 13.06.24"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"84705344X","corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology"}],"language":["eng"],"pubHistory":["1.2016 -"],"part":{"year":"2025","pages":"1-10","issue":"2","text":"10(2025), 2 vom: Feb., Artikel-ID 104107, Seite 1-10","volume":"10","extent":"10"},"name":{"displayForm":["European Society for Medical Oncology"]},"origin":[{"publisherPlace":"[London] ; London","dateIssuedDisp":"2016-","dateIssuedKey":"2016","publisher":"Elsevier ; BMJ"}],"id":{"eki":["84705344X"],"zdb":["2844985-X"],"issn":["2059-7029"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["G. Ku, G.M. Haag, H. Park, V.K. Lam, T.J. George, S.S. Kim, M. Gutierrez, V. Shankaran, S. Stein, C.S. Denlinger, E. Elimova, A. Nagrial, A.R. He, M.B. Sawyer, H.H. Yoon, R. Geva, J. Starr, G. Curigliano, T. Golan, R. von Moos, R. Fritsch, D. Lim, Q. Wang, A. Patel, T. Aoyama, M. Lei, D. Greenawalt, and M. Di Bartolomeo"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"10 January 2025"}],"id":{"doi":["10.1016/j.esmoop.2024.104107"],"eki":["1930547773"]},"note":["Gesehen am 15.07.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1930547773","person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Ku, Geoffrey","given":"Geoffrey","family":"Ku"},{"given":"Georg Martin","family":"Haag","role":"aut","roleDisplay":"VerfasserIn","display":"Haag, Georg Martin"},{"display":"Park, H.","roleDisplay":"VerfasserIn","role":"aut","family":"Park","given":"H."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Lam, V. K.","given":"V. K.","family":"Lam"},{"role":"aut","display":"George, T. J.","roleDisplay":"VerfasserIn","given":"T. J.","family":"George"},{"roleDisplay":"VerfasserIn","display":"Kim, S. S.","role":"aut","family":"Kim","given":"S. S."},{"given":"M.","family":"Gutierrez","role":"aut","roleDisplay":"VerfasserIn","display":"Gutierrez, M."},{"given":"V.","family":"Shankaran","role":"aut","roleDisplay":"VerfasserIn","display":"Shankaran, V."},{"roleDisplay":"VerfasserIn","display":"Stein, S.","role":"aut","family":"Stein","given":"S."},{"given":"C. S.","family":"Denlinger","role":"aut","roleDisplay":"VerfasserIn","display":"Denlinger, C. S."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Elimova, E.","given":"E.","family":"Elimova"},{"roleDisplay":"VerfasserIn","display":"Nagrial, A.","role":"aut","family":"Nagrial","given":"A."},{"family":"He","given":"A. R.","display":"He, A. R.","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Sawyer, M. B.","role":"aut","family":"Sawyer","given":"M. B."},{"display":"Yoon, H. H.","roleDisplay":"VerfasserIn","role":"aut","family":"Yoon","given":"H. H."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Geva, R.","given":"R.","family":"Geva"},{"given":"J.","family":"Starr","role":"aut","display":"Starr, J.","roleDisplay":"VerfasserIn"},{"given":"G.","family":"Curigliano","role":"aut","roleDisplay":"VerfasserIn","display":"Curigliano, G."},{"family":"Golan","given":"T.","display":"Golan, T.","roleDisplay":"VerfasserIn","role":"aut"},{"family":"von Moos","given":"R.","roleDisplay":"VerfasserIn","display":"von Moos, R.","role":"aut"},{"family":"Fritsch","given":"R.","roleDisplay":"VerfasserIn","display":"Fritsch, R.","role":"aut"},{"family":"Lim","given":"D.","roleDisplay":"VerfasserIn","display":"Lim, D.","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Wang, Q.","given":"Q.","family":"Wang"},{"roleDisplay":"VerfasserIn","display":"Patel, A.","role":"aut","family":"Patel","given":"A."},{"family":"Aoyama","given":"T.","roleDisplay":"VerfasserIn","display":"Aoyama, T.","role":"aut"},{"given":"M.","family":"Lei","role":"aut","display":"Lei, M.","roleDisplay":"VerfasserIn"},{"display":"Greenawalt, D.","roleDisplay":"VerfasserIn","role":"aut","family":"Greenawalt","given":"D."},{"given":"M.","family":"Di Bartolomeo","role":"aut","display":"Di Bartolomeo, M.","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer","subtitle":"the phase II FRACTION gastric cancer study","title":"Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer"}]} | ||
| SRT | |a KUGEOFFREYNIVOLUMABC1020 | ||